LEO Pharma and Bayer announced that LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit.
The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids with an annual turnover in 2017 of more than €280 million. It will enable LEO Pharma to expand significantly in key markets worldwide and broaden its therapeutic areas.
Bayer’s global medical dermatology portfolio, which includes prescription treatment solutions for acne (Skinoren®), fungal skin infections (Travogen® and Travocort®) and rosacea (Finacea®), and a range of topical steroids (Advantan®, Nerisona®, and Desonate®), will add complementary treatment areas and strengthen the existing business of LEO Pharma worldwide, allowing the company to more than double sales in some markets. The transaction does not include Bayer’s over-the-counter dermatology portfolio of brands such as Bepanthen® and Canesten® amongst others.
LEO Pharma will acquire the global product rights, except for Afghanistan and Pakistan, and take over the sales and marketing organisations in 14 countries, as well as a factory in Segrate, Italy. In total, around 450 people will join LEO Pharma as part of this transaction. The combination of the local sales and marketing organizations will make LEO Pharma more efficient.
Leo Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Leo Pharma develops and markets products for dermatology, bone remodeling thrombosis and coagulation.